Thread,
Guess no one interested in this one? Money to be made!
Oscar Gruss issues a Speculative Buy rating on Boston Biomedica, Inc.
May 10, 1999 10:44 AM
NEW YORK, May 10 /PRNewswire/ -- The following was released today by Oscar Gruss & Son, a member of the National Association of Securities Dealers CRD# 2091.
Oscar Gruss & Son issued a Speculative BUY rating on Boston Biomedica, Inc., West Bridgewater, MA BBII
In an update, Alan Tuchman, M.D., an equity research analyst at Oscar Gruss, details the background, changes, and investment opportunity at this supplier of quality control infectious disease products which has added a significant biotech arm. Dr. Tuchman believes Boston Biomedica is an interesting hybrid which mitigates some of the usual risks in pure biotech companies.
Dr. Tuchman's recommendation is contained in a research report available from Oscar Gruss & Son Incorporated at 212-514-2345.
Investment Ratings: STRONG BUY: expected total annual return of greater than 25% over the next 12-18 months; BUY: expected total annual return in the range of 15-25% over the next 12-18 months; SPECULATIVE BUY: stock for investors who can afford higher risks; expected total annual return of greater than 25% if anticipated contingencies materialize over the next 12 - 18 months with the potential for high return volatility, lower or negative total annual returns in this time period may be possible; LONG TERM ACCUMULATE: expected total annual return of in the range of 10-20% if anticipated contingencies materialize over the next 12-18 months or longer; HOLD: stock is fairly valued and may provide returns which approximate returns expected from the its peer group in the equity markets over the next 12-18 months, or perhaps less. Other factors considered in the Investment Ratings may include, but are not limited to, the company's risk profile, including earnings predictability, financial position, industry position, technology and product risks, management strengths, and other factors. The required annual return for a specific Investment Rating will be increased for stocks with greater financial, business, and/or earnings risk.
This report is based upon information which Oscar Gruss & Son Incorporated (Oscar Gruss) believes to be reliable. However, neither Oscar Gruss nor any individual acting on the behalf of Oscar Gruss can guarantee the accuracy or completeness of its contents. It does not purport to contain a complete analysis of every material fact concerning any company, industry or security. Oscar Gruss assumes that it will be read in conjunction with other available reports and data. Opinions expressed herein are subject to change without notice. No investor can assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Oscar Gruss and/or our employees and affiliates may have positions in securities which are referred to herein and may make purchases or sales thereof while this report is in circulation. Oscar Gruss or one of its affiliates may from time to time perform investment banking or other services for, or solicit investment banking or other business from a company mentioned in this report. Further information is available upon request. Foreign-currency-denominated securities are subject to fluctuations in currency exchange rates that could have a positive or adverse effect on an investor's return upon the conversion into local currency of dividends or interest received, or proceeds from the sale of such securities. In addition, the value of U.S. dollar-denominated ADRs and the value of U.S. dollar-denominated ordinary shares, or common shares, of foreign issuers can be influenced by fluctuations in currency exchange rates.
SOURCE Oscar Gruss & Son
DrRisk |
